Alkermes (ALKS) Current Assets (2011 - 2026)
Alkermes' (ALKS) quarterly Current Assets came in at $1.5 billion in Q2 2026, down 6.87% year-over-year from $1.6 billion in Q2 2025, and up 12.09% quarter-over-quarter from $1.4 billion in Q1 2026.
Analysis
Alkermes (ALKS) Current Assets (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Current Assets for 16 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Current Assets fell 6.87% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 6.87% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 36.3% from the prior year.
- Current Assets was $1.5 billion for Q2 2026 at Alkermes, up from $1.4 billion in the prior quarter.
- Over five years, Current Assets peaked at $1.9 billion in Q4 2025 and troughed at $1.0 billion in Q1 2022.
- A 5-year average of $1.4 billion and a median of $1.5 billion in 2023 frame the typical range for Current Assets.
- Across the five-year window, Current Assets surged 39.0% in 2023 and retreated 8.14% in 2026, its largest moves.
- Over 5 years, Current Assets stood at $1.1 billion in 2022, then jumped by 31.43% to $1.5 billion in 2023, then dropped by 4.72% to $1.4 billion in 2024, then soared by 36.3% to $1.9 billion in 2025, then slipped by 21.06% to $1.5 billion in 2026.
- The last three Current Assets figures came in at $1.5 billion (Q2 2026), $1.4 billion (Q1 2026), and $1.9 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | 41.36 Bn |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | 36.64 Bn |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | 4.03 Bn |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | 6.03 Bn |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | 3.48 Bn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | 1.52 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.52 Bn |
| Mar 31, 2026 | 1.36 Bn |
| Dec 31, 2025 | 1.93 Bn |
| Sep 30, 2025 | 1.74 Bn |
| Jun 30, 2025 | 1.64 Bn |
| Mar 31, 2025 | 1.48 Bn |
| Dec 31, 2024 | 1.42 Bn |
| Sep 30, 2024 | 1.56 Bn |
| Jun 30, 2024 | 1.54 Bn |
| Mar 31, 2024 | 1.47 Bn |
| Dec 31, 2023 | 1.49 Bn |
| Sep 30, 2023 | 1.46 Bn |
| Jun 30, 2023 | 1.40 Bn |
| Mar 31, 2023 | 1.11 Bn |
| Dec 31, 2022 | 1.13 Bn |
| Sep 30, 2022 | 1.05 Bn |
| Jun 30, 2022 | 1.05 Bn |
| Mar 31, 2022 | 1.01 Bn |
| Dec 31, 2021 | 1.06 Bn |
| Sep 30, 2021 | 1.05 Bn |